Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme
暂无分享,去创建一个
N. Amariglio | G. Rechavi | A. Toren | A. Simon | Tamar Fisher | J. Jacob-Hirsch | G. Lavie | Gil Galanti | I. Kventsel | S. Zeligson | R. Winkler
[1] S. Fulda,et al. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance , 2007, Oncogene.
[2] J. Jean,et al. Hypoxia results in an HIF-1-dependent induction of brain-specific aldolase C in lung epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[3] R. Weimann,et al. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer , 2006, British Journal of Cancer.
[4] Isabelle Camby,et al. Present and potential future issues in glioblastoma treatment , 2006, Expert review of anticancer therapy.
[5] Quynh-Thu Le,et al. Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.
[6] M. Weller,et al. O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.
[7] G. F. Wagner,et al. Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. , 2005, Endocrinology.
[8] A. Mobasheri,et al. Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. , 2005, Histology and histopathology.
[9] N. Amariglio,et al. The nuclear-envelope protein and transcriptional repressor LAP2β interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation , 2005, Journal of Cell Science.
[10] Manish Gala,et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.
[11] J. Hecht,et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[13] J. Itskovitz‐Eldor,et al. CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. , 2005, Stem cells.
[14] N. Amariglio,et al. Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.
[15] N. Banik,et al. Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities , 2004, Molecular Cancer.
[16] G. Koomen,et al. Synthesis and Antitumor Activity of Methyltriazene Prodrugs Simultaneously Releasing DNA-Methylating Agents and the Antiresistance Drug O6-Benzylguanine , 2004 .
[17] David M Jablons,et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[19] I. Germano,et al. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. , 2003, Journal of neurosurgery.
[20] D. Meruelo,et al. Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. , 2003, Cancer research.
[21] L. Gunaratnam,et al. Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.
[22] Z. Dong,et al. Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. , 2003, The American journal of pathology.
[23] N. Ferrara,et al. The biology of VEGF and its receptors , 2003, Nature Medicine.
[24] P. Ratcliffe,et al. Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.
[25] W. Kaelin,et al. HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.
[26] E Pawlak,et al. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids , 2003, British Journal of Cancer.
[27] D. Mottet,et al. CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.
[28] S. Finkelstein,et al. Multifaceted resistance of gliomas to temozolomide. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] Franklin Peale,et al. In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.
[30] S. Gerson. Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Dena Leshkowitz,et al. Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis , 2002, Molecular and Cellular Biology.
[32] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Harris,et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.
[34] K. Srivenugopal,et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] W. Sly,et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.
[36] A. Harris,et al. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling , 2000, Oncogene.
[37] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[38] K. Hillan,et al. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. , 1999, Anticancer research.
[39] G. Weiss,et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] F. Ismail-Beigi,et al. Regulation of glucose transport by hypoxia. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[41] A. MacKenzie,et al. The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.
[42] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[44] B. Teicher,et al. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma , 1996, Cancer Chemotherapy and Pharmacology.
[45] G. Semenza,et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.
[46] E. Newlands,et al. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.
[47] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[48] A. Pegg,et al. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.
[49] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.